SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 8, 2002
-----------------------------
Celsion Corporation
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14242 52-1256615
----------------------------- -------------------------- --------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
10220-I Old Columbia Road, Columbia, Maryland 21046-1705
-------------------------------------------------------------------------------
(Address of principal executive office) (Zip Code)
Registrant's telephone number, including area code: (410) 290-5390
---------------------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
ITEM 5. OTHER EVENTS
On April 8, 2002, the Company issued a press release reporting, among other
things, on the filing of an Investigational New Drug Application with the Food
and Drug Administration for its temperature-sensitive liposome compound in the
treatment of prostate cancer. A copy of the press release is attached as Exhibit
99.1 to this Report on Form 8-K.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CELSION CORPORATION
Date: April 9, 2002 By: /s/ John Mon
---------------------------------
John Mon
Secretary
-3-
EXHIBIT INDEX
Exhibit Description
------- -----------
99.1 Press Release dated April 8 2002.